ROPSACITINIB
Ropsacitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase JAK1, tyrosine-protein kinase JAK2, and non-receptor tyrosine-protein kinase TYK2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
No data
Commercial
No data
Clinical
No data
Drug
General
| Drug common name | ROPSACITINIB |
| INN | ropsacitinib |
| Description | Ropsacitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase JAK1, tyrosine-protein kinase JAK2, and non-receptor tyrosine-protein kinase TYK2. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; janus kinase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cn1cc(-c2cn3nccc3c(-c3cnn([C@]4(CC#N)C[C@@H](C#N)C4)c3)n2)cn1 |
Identifiers
| PDB | — |
| CAS-ID | 2127109-84-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4459585 |
| ChEBI ID | — |
| PubChem CID | 130339268 |
| DrugBank | DB18709 |
| UNII ID | HY5SOV7O0Q (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use